BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 17288681)

  • 1. Pharmacokinetic model and simulations of dose conversion from immediate- to extended-release tramadol.
    Murthy BP; Skee DM; Danyluk AP; Brett V; Vorsanger GJ; Moskovitz BL
    Curr Med Res Opin; 2007 Feb; 23(2):275-84. PubMed ID: 17288681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of extended-release versus conventional tramadol/acetaminophen fixed-dose combination tablets: an open-label, 2-treatment, multiple-dose, randomized-sequence crossover study in healthy korean male volunteers.
    Yi S; Chung YJ; Kim TE; Shin HS; Yoon SH; Cho JY; Jang IJ; Shin SG; Yu KS
    Clin Ther; 2011 Jun; 33(6):728-37. PubMed ID: 21704237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
    Jenner P; Könen-Bergmann M; Schepers C; Haertter S
    Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic simulation for switching from galantamine immediate-release to extended-release formulation.
    Hing JP; Piotrovsky V; Kimko H; Brashear HR; Zhao Q
    Curr Med Res Opin; 2005 Apr; 21(4):483-8. PubMed ID: 15899095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended-release Tramadol (ULTRAM ER): a pharmacotherapeutic, pharmacokinetic, and pharmacodynamic focus on effectiveness and safety in patients with chronic/persistent pain.
    Barkin RL
    Am J Ther; 2008; 15(2):157-66. PubMed ID: 18356636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative pharmacokinetics of a once-daily tramadol extended-release tablet and an immediate-release reference product following single-dose and multiple-dose administration.
    Karhu D; Fradette C; Potgieter MA; Ferreira MM; Terblanché J
    J Clin Pharmacol; 2010 May; 50(5):544-53. PubMed ID: 20051587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and pharmacodynamic properties of tramadol IR and SR in elderly patients: a prospective, age-group-controlled study.
    Likar R; Wittels M; Molnar M; Kager I; Ziervogel G; Sittl R
    Clin Ther; 2006 Dec; 28(12):2022-39. PubMed ID: 17296459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, 8-week crossover study of once-daily controlled-release tramadol versus immediate-release tramadol taken as needed for chronic noncancer pain.
    Beaulieu AD; Peloso P; Bensen W; Clark AJ; Watson CP; Gardner-Nix J; Thomson G; Piraino PS; Eisenhoffer J; Harsanyi Z; Darke AC
    Clin Ther; 2007 Jan; 29(1):49-60. PubMed ID: 17379046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tramadol extended-release formulations in the management of pain due to osteoarthritis.
    Mongin G
    Expert Rev Neurother; 2007 Dec; 7(12):1775-84. PubMed ID: 18052769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open-label study of the safety and effectiveness of long-term therapy with extended-release tramadol in the management of chronic nonmalignant pain.
    Pascual ML; Fleming RR; Gana TJ; Vorsanger GJ
    Curr Med Res Opin; 2007 Oct; 23(10):2531-42. PubMed ID: 17825129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative bioavailability between two Tramadol once-daily oral formulations.
    Hernandez-Lopez C; Martinez-Farnos L; Karhu D; Perez-Campos T; Rovira S; Encina G
    Methods Find Exp Clin Pharmacol; 2006; 28(6):373-8. PubMed ID: 16894407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioavailability of divalproex extended-release formulation relative to the divalproex delayed-release formulation.
    Dutta S; Zhang Y
    Biopharm Drug Dispos; 2004 Nov; 25(8):345-52. PubMed ID: 15378557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-daily dosing is appropriate for extended-release divalproex over a wide dose range, but not for enteric-coated, delayed-release divalproex: evidence via computer simulations and implications for epilepsy therapy.
    Reed RC; Dutta S; Liu W
    Epilepsy Res; 2009 Dec; 87(2-3):260-7. PubMed ID: 19892524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Importance of the formulation for a chronopharmacologically optimised way of pain therapy. Results of a comparative bioavailability study of tramadol extended-release capsules after single-dose evening versus morning administration].
    Warnke A; Schug B; Vanderbist F; Blume H
    MMW Fortschr Med; 2008 Apr; 150 Suppl 1():36-42. PubMed ID: 18540331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release.
    Figueroa C; Brecher M; Hamer-Maansson JE; Winter H
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):199-204. PubMed ID: 18948162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post hoc analysis of a randomized, double-blind, placebo-controlled efficacy and tolerability study of tramadol extended release for the treatment of osteoarthritis pain in geriatric patients.
    Vorsanger G; Xiang J; Jordan D; Farrell J
    Clin Ther; 2007; 29 Suppl():2520-35. PubMed ID: 18164919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic properties of tramadol sustained release capsules. 1st communication: investigation of dose linearity.
    Schulz HU; Raber M; Schürer M; Amschler S; Momberger H
    Arzneimittelforschung; 1999 Jul; 49(7):582-7. PubMed ID: 10442205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peritoneal microdialysis in freely moving rodents: an alternative to blood sampling for pharmacokinetic studies in the rat and the mouse.
    Beier H; Kaiser K; Langhans M; Malmendier K; Sluijsmans I; Weiher J
    Eur J Pharm Sci; 2007 Jan; 30(1):75-83. PubMed ID: 17140776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two open-label, randomized, crossover studies assessing the bioequivalence of ofloxacin administered as immediate-and extended-release formulations in healthy subjects.
    Marier JF; Ducharme MP; DiMarco M; Di Spirito M; Morelli G; Tippabhotla SK; Badri N; Rampal A; Monif T
    Clin Ther; 2006 Dec; 28(12):2070-80. PubMed ID: 17296463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: results of two randomized studies in patients with Parkinson's disease.
    Tompson DJ; Vearer D
    Clin Ther; 2007 Dec; 29(12):2654-66. PubMed ID: 18201581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.